Drug
Extended-Release Naltrexone
Extended-Release Naltrexone is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
80%(4 trials)
Phase Distribution
Ph phase_1
1
20%
Ph phase_2
1
20%
Ph phase_3
1
20%
Ph phase_4
2
40%
Phase Distribution
1
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)
Phase 42 (40.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
NCT05262270
completedphase_4
Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry
NCT01999946
completedphase_4
Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment
NCT02032433
completedphase_1
Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations
NCT01246401
completedphase_3
Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail
NCT01180647
Clinical Trials (5)
Showing 5 of 5 trials
NCT05262270Phase 2
Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
NCT01999946Phase 4
Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry
NCT02032433Phase 4
Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment
NCT01246401Phase 1
Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations
NCT01180647Phase 3
Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5